两种抗VEGF药物治疗渗出性年龄相关性黄斑病变的疗效

发布时间：2018-05-20 23:28

本文选题：年龄相关性黄斑变性 + 雷珠单抗　；参考：《国际眼科杂志》2016年08期

【摘要】：目的:观察雷珠单抗和康柏西普治疗湿性年龄相关性黄斑变性的临床疗效。方法:回顾性病例系列研究。分析30例30眼雷珠单抗玻璃体腔注射0.5mg每月1次,连续3次治疗湿性老年黄斑变性的病例和28例30眼康柏西普玻璃体腔注射0.5mg每月1次,连续3次治疗湿性老年黄斑变性的病例,比较两组分别在玻璃体腔注药1mo后的最佳矫正视力及OCT变化情况。结果:连续3次玻璃体腔注药,每次治疗后1mo与治疗前相比,A组BCVA平均值提高,CMT平均值降低,差异具有统计学意义(P0.05);B组BCVA平均值提高,CMT平均值亦降低,差异具有统计学意义(P0.05),两组间比较BCVA变化、CMT变化差异不具有统计学意义(P0.05)。结论:雷珠单抗和康柏西普治疗均能有效控制湿性AMD患者病情发展并改善视力,治疗3mo内两种药物疗效的比较无统计学意义。
[Abstract]:Objective: to observe the clinical effect of Leizhu McAb and Compactopril in the treatment of wet age-related macular degeneration. Methods: retrospective case series study. 30 cases (30 eyes) of Leizhu McAb were injected with 0.5mg once a month, 3 consecutive times for the treatment of wet senile macular degeneration, and 30 cases (30 eyes) for 0.5mg injected into the vitreous cavity of 30 cases (30 eyes), and 30 eyes (30 eyes) for the treatment of wettable senile macular degeneration once a month. The best corrected visual acuity (BCVA) and the changes of OCT were compared between the two groups after intravitreal injection of 1mo. Results: after three consecutive intravitreous injections, the average value of BCVA in group A was significantly lower than that in group A after each treatment, and the average value of BCVA in group B was significantly lower than that in group A (P 0.05). The difference was statistically significant (P 0.05). There was no significant difference in BCVA changes between the two groups (P 0.05). Conclusion: both Leizhu McAb and Combortopril can effectively control the development and improve the visual acuity of patients with wet AMD. There is no significant difference between the two drugs in the treatment of 3mo.
【作者单位】：重庆医科大学附属第一医院眼科;
【分类号】：R774.5

【相似文献】